Gilead Sciences | GILD - Ebitda





Ebitda Veränderung Datum
AbbVie USD 6.91B 3.22B 2026-06
Agios Pharmaceuticals USD -109.2M 540K 2026-06
ALKERMES USD 120.06M 19.15M 2026-09
Alnylam Pharmaceuticals USD 360.27M 114.93M 2026-09
Amgen USD 5.8B 1.25B 2026-09
Biogen USD 450.8M 198.9M 2026-06
BioMarin Pharmaceutical USD 222.32M 76.27M 2026-06
Bristol-Myers Squibb USD 3.48B 1.6B 2026-09
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eli Lilly USD 9.46B 3.54B 2026-09
Gilead Sciences USD -9.31B 12.82B 2026-06
GlaxoSmithKline GBP 3.51B 734M 2026-06
Glaxosmithkline GBP 2.93B 154M 2026-09
Incyte USD 778.57M 410.6M 2026-06
J&J USD 8.99B 721M 2026-06
Merck USD 1.42B 2.97B 2026-06
Moderna USD -1.26B 468M 2026-03
Neurocrine Biosciences USD 375.3M 185.4M 2026-09
Novartis USD 8.62B 2.14B 2026-09
Pfizer USD 6.36B 350M 2026-09
PTC Therapeutics USD 161.9M 99.92M 2026-06
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.66B 695.2M 2026-06
Sanofi EUR 5.79B 2.1B 2026-09
Sarepta Therapeutics USD 30.17M 345.31M 2026-06
United Therapeutics USD 334.2M 20.8M 2026-09
Vertex Pharmaceuticals USD 1.33B 130.5M 2026-06